Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novartis AGLTS:0QM7 80 PS Ratio is 0.00 as of Jul. 19, 2026. GuruFocus rates LTS:0QM7 with a GF Score™ of 80/100. The stock has 7 warning signs investors should review. Among 954 Drug Manufacturers companies, Novartis AG ranks worse than 75.68% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Novartis AG's share price is CHF0.00.
Novartis AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF20.94. Hence, Novartis AG's PS Ratio for today is 0.00.
Warning Sign:
Novartis AG stock PS Ratio (=5.36) is close to 10-year high of 5.49.
The historical rank and industry rank for Novartis AG's PS Ratio or its related term are showing as below:
LTS:0QM7'
s PS Ratio Range Over the Past 10 Years
Min: 2.85 Med: 4.05 Max: 5.49
Current: 5.36
During the past 13 years, Novartis AG's highest PS Ratio was 5.49. The lowest was 2.85. And the median was 4.05.
LTS:0QM7's PS Ratio is ranked worse than 75.68% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs LTS:0QM7: 5.36
Novartis AG revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Novartis AG was 0.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.80% per year.
During the past 13 years, Novartis AG's highest 3-Year average Revenue per Share Growth Rate was 13.00% per year. The lowest was -5.20% per year. And the median was 1.70% per year.
Back to Basics: PS Ratio
Novartis AG (LTS:0QM7) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Novartis AG PS Ratio Related Terms
Novartis AG PS Ratio Historical Data
* Premium members only.
The historical data trend for Novartis AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Novartis AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Novartis AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Novartis AG's Share Price of today is CHF0.00. Novartis AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF20.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Novartis AG (LTS:0QM7) has a PS Ratio of 0.00 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Novartis AG and its competitors. Over the past decade, Novartis AG's PS Ratio has ranged from 2.85 to 5.49. According to the industry distribution chart, Novartis AG ranks #722 out of 954 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is Novartis AG's PS Ratio too high?
Novartis AG's current PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 2.85 to a high of 5.49. Based on the distribution chart, Novartis AG ranks #722 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Novartis AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #722 out of 954 companies for PS Ratio. This places Novartis AG in the lower half of its industry. The industry median PS Ratio is 2.32. Historically, Novartis AG's own PS Ratio has ranged from 2.85 to 5.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Novartis AG and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis AG's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (LTS:0QM7) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Novartis AG's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Novartis AG (LTS:0QM7), the current PS Ratio is 0.00 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QM7 has been successfully added to your 
